{
  "source": "PA-Notification-Entyvio-SC.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1436-3\nProgram Prior Authorization/Notification\nMedication *Entyvio® (vedolizumab)\n*This program applies to the subcutaneous formulation of vedolizumab\nP&T Approval Date 4/2024, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nEntyvio (vedolizumab) for subcutaneous use is an integrin receptor antagonist indicated in adults\nfor the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease\n(CD).\n2. Coverage Criteriaa:\nA. Ulcerative Colitis\n1. Initial Authorization\na. Entyvio for subcutaneous use will be approved based on both of the following\ncriteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) Patient is not receiving Entyvio in combination with a targeted\nimmunomodulator [e.g., adalimumab, Omvoh (mirikizumab-mrkz), Rinvoq\n(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Ustekinumab, Zeposia\n(ozanimod)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Entyvio for subcutaneous use will be approved based on both of the following\ncriteria:\n(1) Documentation of positive clinical response to Entyvio therapy\n-AND-\n(2) Patient is not receiving Entyvio in combination with a targeted\nimmunomodulator [e.g., adalimumab, Omvoh (mirikizumab-mrkz), Rinvoq\n(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Ustekinumab, Zeposia\n© 2025 UnitedHealthcare Services, Inc.\n1\n(ozanimod)]\nAuthorization will be issued for 12 months.\nB. Crohn’s Disease\n1. Initial Authorization\na. Entyvio for subcutaneous use will be approved based on both of the following\ncriteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) Patient is not receiving Entyvio in combination with a targeted\nimmunomodulator [e.g., adalimumab, Omvoh (mirikizumab-mrkz), Rinvoq\n(upadacitinib), Simponi (golimumab), Sky",
    "e Crohn’s disease\n-AND-\n(2) Patient is not receiving Entyvio in combination with a targeted\nimmunomodulator [e.g., adalimumab, Omvoh (mirikizumab-mrkz), Rinvoq\n(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Ustekinumab, Zeposia\n(ozanimod)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Entyvio for subcutaneous use will be approved based on both of the following\ncriteria:\n(1) Documentation of positive clinical response to Entyvio therapy\n-AND-\n(2) Patient is not receiving Entyvio in combination with a targeted\nimmunomodulator [e.g., adalimumab, Omvoh (mirikizumab-mrkz), Rinvoq\n(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Ustekinumab, Zeposia\n(ozanimod)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n© 2025 UnitedHealthcare Services, Inc.\n2\n• Supply limits may be in place.\n4. References:\n1. Entyvio [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; April 2024.\nProgram Prior Authorization/Notification – Entyvio (vedolizumab)\nChange Control\n4/2024 New program.\n5/2024 Added coverage criteria for Crohn’s disease. Updated background and\nreference.\n5/2025 Annual review with no change to coverage criteria. Updated example\nwith no change to clinical intent.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}